866-997-4948(US-Canada Toll Free)

International Stroke Conference 2011: Review and Analysis

Published By :

GlobalData

Published Date : Mar 2011

Category :

Therapeutic Area

No. of Pages : 14 Pages


GlobalData, the industry analysis specialist, has released its new conference alerts, International Stroke Conference 2011: Review and Analysis. The conference alert is an essential source of information and analysis on the emerging therapies and new disease management techniques.

The annual meeting of International Stroke Conference 2011 was held in Los Angeles, the US, between February 811, 2011. The two-and-a-half day conference included 900 presentations which highlighted the most recent advances in cerebral circulation and brain function, clinical stroke research and outcomes, rehabilitation science and surgery. Approximately 6,000 physicians from the different countries attended the conference.

Scope
  • The report provides complete coverage of conference. Its scope includes -
  • Qualitative analysis of the studies and clinical trials presented at the conference and their impact on the key market dynamics and future treatment paradigm.
  • Review of pre- and post-conference KOL/analyst comments
  • Market revenue data for 2010 and forecast forward to 2017 for a specific disease area (if the conference being covered is focused on a specific disease area).
  • Review of key industry trends and events which are likely to impact and change the dynamics of the concerned disease markets in the long run.
Reasons to buy

The report will serve to facilitate your decision making in the concerned therapy areas. It will allow you to -
  • Develop business strategies by understanding the trends and developments that are driving or are expected to drive the market in the concerned disease areas.
  • Explore M&A opportunities by identifying key products and market players.
  • Develop market-entry and market expansion strategies.
  • Identify key players best positioned to take advantage of the market opportunities.
  • Make more informed business decisions from the insightful and in-depth analysis of the market and the factors influencing the same.
Table of Content:

1 Table of contents

1 Table of contents 1

2 Summary 2
2.1 Key Takeaways 2

3 International Stroke Conference 2011: Key Highlights 3
3.1 Molecule Brain-Derived Neurotrophic Factor (BDNF) Administered Beginning Three Days After Stroke: A Favorable Outcome 3
3.2 Albumin in Acute Stroke (ALIAS) Part 1 Trial: An Exploratory Efficacy Analysis 3
3.3 Stroke Sequel among Elderly Population: A Meta-Analysis of Duration 1998-2008 4
3.4 FLAME: A Trial with Fluoxetine in Motor Recovery of Patients with Acute Ischemic Stroke 4
3.5 The Novel TrkB Agonist, 7, 8-Dihydroxyflavone Enhances Stem Cell Mobilization after Stroke 5
3.6 The Selective TrkB Agonist, 7, 8-Dihydroxyflavone, Enhances Motor Performance and Promotes Motor Map Integrity Following Cortical Stroke 6
3.7 Safety and Efficacy of Intravenous Thrombolysis Beyond 4.5 Hours in Acute Ischemic Stroke Patients Selected By Perfusion Computed Tomography 6
3.8 The Effect of Intravenous Thrombolysis Using Recombinant Tissue Plasminogen Activator (rt-PA) For Acute Ischemic Stroke 7
3.9 Elevated High-Sensitivity C-reactive protein (hsCRP) in Acute Stage Cerebral Infarction Predicts Progression of Carotid Intima-media Thickness 7
3.10 Acute Stroke Trials in the First Decade of the 21st Century: An Overview 8
3.11 THR-18 Peptide, a Modulator of tPA action: A Summary of Preclinical and Clinical Studies 9
3.12 Therapeutic Benefit of Combination Simvastatin and Human Umbilical Cord Blood Cells Treatment of Stroke: Neurogenesis, Vascular and White Matter Remodeling 9
3.13 Safety and Efficacy of Early Blood Pressure Reduction in Acute Ischemic Stroke: An Interim Analysis of VENTURE Trial 10
3.14 Angiotensin Receptor Blockade in Acute Stroke: Results from the Scandinavian Candesartan Acute Stroke Trial (SCAST) 11
3.15 Let 7f microRNA as a Therapeutic Target Following Stroke 11
3.16 Advanced Macular Degeneration Is Associated With an Increased Risk of Bleeding Stroke in Elderly 12
3.17 The Effect of Clazosentan on Clinical Outcome after Aneurysmal Subarachnoid Hemorrhage and surgical Clipping: Results of the CONSCIOUS-2 Study 12

4 Appendix 13

4.1 Abbreviations 13
4.2 Disclaimer 14

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *